On April 16, 2024 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, reported that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio (Press release, Veracyte, APR 16, 2024, View Source [SID1234642107]). Studies to be presented include those that evaluate the clinical utility of the company’s Decipher tests in guiding treatment decisions for patients with prostate or bladder cancer. Other presentations will explore new insights into these cancers’ underlying biology, which researchers derived through use of Veracyte’s whole-transcriptome-based Decipher GRID research tool.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data being presented at AUA 2024 expands the extensive clinical evidence supporting our Decipher Prostate and Decipher Bladder tests," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "They also highlight Veracyte’s commitment to collaborating with leading researchers to help understand the biological underpinnings of urologic cancers and advance the science around the disease areas we serve."

The following abstracts will be presented in the Henry B. González Convention Center:

Title:

High Decipher score defines the subgroup most at risk of metastatic progression among patients with lower grade tumors classified as NCCN high-risk based on elevated prostate-specific antigen level alone

Presenter:

David Han, M.D., Columbia University Irving Medical Center

Format:

Poster (MP41-14)

Date/Time:

Saturday, May 4, 2024 / 3:30 p.m. to 5:30 p.m. CT

Room #:

304B

Title:

Decipher Predicts Clinically Significant Upgrading on Final Radical Prostatectomy Pathology

Presenter:

John Sheng, M.D., Rutgers New Jersey Medical School

Format:

Poster (MP49-09)

Date/Time:

Sunday, May 5, 2024 / 7:00 a.m. to 9:00 a.m. CT

Room #:

221B

Title:

Genomic Signatures Associated with Adverse Pathologic Features at Radical Prostatectomy Among Active Surveillance Eligible Men

Presenter:

Eric Li, M.D., Northwestern University

Format:

Poster (MP41-09)

Date/Time:

Saturday, May 4, 2024 / 3:30 p.m. to 5:30 p.m. CT

Room #:

304B

Title:

Variation in Prostate Cancer Genomic Subtypes Across Prostate Magnetic Resonance Imaging PIRADS Scores and Race

Presenter:

Nimrod Barashi Gozal, M.D., Washington University in St. Louis

Format:

Podium Presentation (PD42-01)

Date/Time:

Sunday, May 5, 2024 / 9:30 a.m. to 9:40 a.m. CT

Room #:

303A

Title:

Transcriptomic Features of Clinically Localized Prostate Cancer Arising from Distinct Prostate Zonal Regions

Presenter:

Ross Liao, M.D., Cleveland Clinic

Format:

Poster (MP41-13)

Date/Time:

Saturday, May 4, 2024 / 3:30 p.m. to 5:30 p.m. CT

Room #:

304B

Title:

Glucagon-like peptide-1 Expression in Prostate Cancer

Presenter:

Mohammed Shahait, M.D., Private Practice

Format:

Poster (MP05-10)

Date/Time:

Friday, May 3, 2024 / 7:00 a.m. to 9:00 a.m. CT

Room #:

221C

Title:

Molecular subtyping for predicting non-organ confined disease and survival outcomes after radical cystectomy in clinical high-grade T1 and T2 bladder cancer patients

Presenter:

Yair Lotan, M.D., UT Southwestern Medical Center

Format:

Poster (MP15-07)

Date/Time:

Friday, May 3, 2024 / 1:00 p.m. to 3:00 p.m. CT

Room #:

221C

Title:

The stroma-rich consensus bladder cancer subtype correlates with improved prognosis after neoadjuvant immunotherapy and radical cystectomy

Presenter:

Joep De Jong, Ph.D., Erasmus MC, The Netherlands

Format:

Podium Presentation (PD14-05)

Date/Time:

Friday, May 3, 2024 / 4:10 p.m. to 4:20 p.m. CT

Room #:

301A

Title:

A lncRNA-based classifier identifies high grade T1 bladder cancer patients with excellent outcomes after radical cystectomy

Presenter:

Yair Lotan, M.D., UT Southwestern Medical Center

Format:

Poster (MP15-02)

Date/Time:

Friday, May 3, 2024 / 1:00 p.m. to 3:00 p.m. CT

Room #:

221C

Additional information regarding these presentations and Veracyte’s participation at AUA 2024 can be found at the company’s booth (#607).

About Decipher Prostate

The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients with prostate cancer. The test is performed on biopsy or surgically resected samples and provides an accurate risk of developing metastasis with standard treatment. Armed with this information, the physician can better personalize their patients’ care and may recommend less-intensive options for those at lower risk or earlier, more-intensive treatment for those at higher risk of metastasis. The Decipher Prostate test has been validated in more than 75 studies involving more than 100,000 patients. More information about the Decipher Prostate test can be found here.

About Decipher Bladder

The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.

About Decipher GRID

The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More Information about Decipher GRID can be found here.